Status:
UNKNOWN
IORT in Local Advanced Laryngocarcinoma
Lead Sponsor:
Tianjin First Central Hospital
Conditions:
Laryngeal Neoplasms
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The incidence of laryngeal cancer accounts for about 1 \~ 5% of the total body tumors. For the surgical treatment of laryngeal cancer, the development trend of laryngocarcinoma treatment is to improve...
Eligibility Criteria
Inclusion
- adults over the age of 18;
- radiographic or pathological diagnosis of local advanced laryngocarcinoma (according to NCCN guidelines);
- the expected survival time ≥ 3 months;
- sign informed consent for treatment and research with self-knowledge.
Exclusion
- there is distant metastasis;
- pregnant women;
- patients with CT/MRI contraindications;
- the patient fails to receive treatment and/or follow-up as scheduled;
- bad fluid and organ function decompensation;
- multiple primary cancers;
- patients participating in other trials.
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2023
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04278638
Start Date
January 1 2018
End Date
December 1 2023
Last Update
October 23 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin First Central Hospital
Tianjin, Tianjin Municipality, China, 300000